Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GUSB | P08236 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28051087 | 0.80 | GUSB (0.61) | PDE5ARAB9ASMN1; SMN2GUSBMAPT | |
| SCHEMBL29740691 | 0.78 | GUSB (0.78) | RAB9AGUSB | |
| SCHEMBL1084872 | 0.78 | GUSB (0.78) | RAB9AGUSB | |
| SCHEMBL29398836 | 0.76 | KDM4E (0.57) | PDE5ARAB9ASMN1; SMN2GUSBMAPT | |
| SCHEMBL17786623 | 0.76 | FGFR1 (0.49) | PDE5AGUSBFGFR1FGFR2 | |
| SCHEMBL259507 | 0.74 | RAB9A (0.59) | RAB9ASMN1; SMN2MAPT | |
| Water SCHEMBL31017622 | 0.74 | SMN1; SMN2 (0.58) | PDE5ARAB9ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL13789421 | 0.73 | SMN1; SMN2 (0.53) | PDE5ARAB9ASMN1; SMN2MAPTRXFP1 | |
| SCHEMBL183430 | 0.73 | GUSB (0.59) | GUSB | |
| SCHEMBL183953 | 0.73 | GUSB (0.59) | PDE5ARAB9AGUSBFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| WO-2007146284-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | KCNJ1, KCNJ2, TRPV1 | PDE5A 1368/4885RAB9A 3260/4885SMN1; SMN2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.